FY2025 EPS Estimates for Journey Medical Reduced by Analyst

Key Points

• Analysts at Roth Capital have decreased their FY2025 earnings per share forecast for Journey Medical from ($0.23) to ($0.32).
• Journey Medical's stock has experienced a slight decline, trading down 0.8% to $7.20, as analysts have provided mixed ratings, with some downgrading their outlook.
• The company reported a quarterly earnings miss, with an EPS of ($0.16), falling short of the consensus estimate of ($0.07).

Journey Medical Corporation (NASDAQ:DERM - Free Report) - Equities researchers at Roth Capital decreased their FY2025 earnings estimates for Journey Medical in a report released on Tuesday, August 12th. Roth Capital analyst J. Wittes now expects that the company will earn ($0.32) per share for the year, down from their prior forecast of ($0.23). The consensus estimate for Journey Medical's current full-year earnings is ($1.02) per share.

Journey Medical (NASDAQ:DERM - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.09). The business had revenue of $15.01 million during the quarter, compared to analyst estimates of $14.93 million. Journey Medical had a negative net margin of 15.49% and a negative return on equity of 48.69%.

A number of other analysts also recently issued reports on the company. Alliance Global Partners reaffirmed a "buy" rating on shares of Journey Medical in a research note on Thursday, May 15th. Wall Street Zen cut shares of Journey Medical from a "buy" rating to a "hold" rating in a research report on Sunday, July 6th. Finally, Lake Street Capital reiterated a "buy" rating and issued a $13.00 target price (up from $9.00) on shares of Journey Medical in a report on Wednesday, August 13th.

Journey Medical Price Performance

Shares of NASDAQ:DERM traded up $0.05 during midday trading on Friday, hitting $7.00. The company had a trading volume of 253,706 shares, compared to its average volume of 185,627. Journey Medical has a twelve month low of $3.54 and a twelve month high of $8.90. The stock has a market cap of $163.10 million, a price-to-earnings ratio of -18.42 and a beta of 0.80. The company has a debt-to-equity ratio of 1.11, a current ratio of 1.27 and a quick ratio of 0.95. The business's 50-day simple moving average is $7.15 and its 200-day simple moving average is $6.55.

Hedge Funds Weigh In On Journey Medical

A number of hedge funds have recently modified their holdings of the business. Police & Firemen s Retirement System of New Jersey acquired a new position in Journey Medical in the second quarter valued at about $29,000. Bank of America Corp DE lifted its holdings in shares of Journey Medical by 4,707.0% in the 2nd quarter. Bank of America Corp DE now owns 4,134 shares of the company's stock worth $30,000 after acquiring an additional 4,048 shares during the last quarter. Raymond James Financial Inc. acquired a new position in shares of Journey Medical in the 2nd quarter worth approximately $36,000. JPMorgan Chase & Co. purchased a new position in shares of Journey Medical during the 2nd quarter worth approximately $41,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Journey Medical in the 2nd quarter valued at approximately $48,000. 7.25% of the stock is currently owned by hedge funds and other institutional investors.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.